| Lenalidomide studied in …STUDIED_INderived200 of 863show all (up to 200) |
|---|
| → studied in | NCT01559935Phase 2 · completed Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma,T-Cell/Histiocyte-Rich Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07605416Phase 2 · recruiting Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial · 863 trials list this drug (249 active) | — | — | Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02180711Phase 1/Phase 2 · active not recruiting Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · 863 trials list this drug (249 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050097Phase 1 · active not recruiting A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · 863 trials list this drug (249 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05288062Phase 2 · terminated Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · 863 trials list this drug (249 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02538198Phase 2 · active not recruiting Lenalidomide Maintenance in Plasma Cell Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02619682Phase 2 · completed Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Transplant-Related Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04133636Phase 2 · active not recruiting A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04876248Phase 2 · active not recruiting Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923893Phase 3 · active not recruiting A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05438043Phase 3 · active not recruiting A Study of Daratumumab · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552222Phase 3 · recruiting A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572229Phase 2 · active not recruiting Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05623020Phase 3 · recruiting A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06169215Phase 2 · active not recruiting Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06284122Phase 3 · active not recruiting Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577025Phase 2 · active not recruiting A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06768489Phase 1 · recruiting A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma,AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07665450Phase 3 · recruiting A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | B-Cell Malignant Neoplasm,Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04301076Phase 1 · recruiting Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) · 863 trials list this drug (249 active) | — | — | Adult T-Cell Leukemia/Lymphoma,Acute Adult T-Cell Leukemia/Lymphoma,Chronic Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06220032Phase 3 · recruiting Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05861050Phase 1/Phase 2 · suspended Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Mantle Cell Lymphoma,Blastoid Variant Mantle Cell Lymphoma,Pleomorphic Variant Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07095452Phase 2/Phase 3 · recruiting A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04096066Phase 3 · active not recruiting A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06997081Phase 2 · recruiting ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07639138Phase 2 · recruiting Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC · 863 trials list this drug (249 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830485Phase 2 · not yet recruiting CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | Composite Lymphoma,Aggressive B-Cell Non-Hodgkin Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615636Phase 2 · recruiting A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL · 863 trials list this drug (249 active) | — | — | B-Cell Malignant Neoplasm,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652905Phase 2 · recruiting CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia · 863 trials list this drug (249 active) | — | — | Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04071457Phase 3 · active not recruiting S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05827016Phase 3 · active not recruiting A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01352962Phase 1 · completed Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors · 863 trials list this drug (249 active) | — | — | Urethra Neoplasm,Malignant Urethral Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446236Phase 1 · active not recruiting Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635189Phase 2 · active not recruiting Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03004287Phase 2 · active not recruiting 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04497961Phase 2 · active not recruiting A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06182774Phase 3 · recruiting Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01936532Phase 2 · completed Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246086Phase 1/Phase 2 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05201248Phase 1/Phase 2 · active not recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07308132Phase 1 · recruiting A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · 863 trials list this drug (249 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma,High Grade B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01522976Phase 2 · active not recruiting Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia · 863 trials list this drug (249 active) | — | — | Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia,Myelodysplastic Syndrome with Excess Blasts+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04623541Phase 1/Phase 2 · active not recruiting Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome · 863 trials list this drug (249 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04663347Phase 1/Phase 2 · active not recruiting Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01711554Phase 1 · active not recruiting Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma · 863 trials list this drug (249 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · 863 trials list this drug (249 active) | — | — | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680052Phase 3 · active not recruiting A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583617Phase 1/Phase 2 · recruiting A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084936Phase 3 · recruiting A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00843882Phase 3 · active not recruiting Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia · 863 trials list this drug (249 active) | — | — | Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia,De Novo Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900882Phase 2 · completed SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05279300Phase 1 · suspended A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas · 863 trials list this drug (249 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00098475Phase 3 · active not recruiting Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00602641Phase 3 · active not recruiting Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01856192Phase 2 · active not recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05344833Phase 2 · recruiting Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00114101Phase 3 · active not recruiting Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02911142Phase 1/Phase 2 · active not recruiting Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma · 863 trials list this drug (249 active) | — | — | B-Cell Neoplasm,Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06112847Phase 2 · active not recruiting Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06087653Phase 1/Phase 2 · recruiting Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02160015Phase 1 · active not recruiting Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery · 863 trials list this drug (249 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404088Phase 2 · active not recruiting Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792502Phase 2 · recruiting Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma · 863 trials list this drug (249 active) | — | — | B-Cell Malignant Neoplasm,Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03937635Phase 3 · recruiting Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma · 863 trials list this drug (249 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04566328Phase 3 · recruiting Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07485647Phase 2 · recruiting Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950165Phase 1/Phase 2 · active not recruiting A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma · 863 trials list this drug (249 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06042725Phase 1 · active not recruiting MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07285239Phase 3 · recruiting Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341867Phase 1 · recruiting Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05091372Phase 2 · recruiting Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05259839Phase 1 · active not recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06149286Phase 3 · recruiting A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764861Phase 2 · not yet recruiting A Open-Label Phase in Participants With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764978Phase 3 · recruiting Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03409432Phase 2 · completed Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Lymphomatoid Papulosis,Primary Cutaneous Anaplastic Large Cell Lymphoma,Primary Cutaneous T-Cell Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04447027Phase 1 · completed Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies · 863 trials list this drug (249 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06762431Phase 1/Phase 2 · recruiting Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. · 863 trials list this drug (249 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07562022Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792825Phase 2 · recruiting HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06918002Phase 3 · recruiting Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07753369Phase 3 · not yet recruiting A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06207799Phase 2 · recruiting Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01169337Phase 3 · active not recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Smoldering Multiple Myeloma,Light Chain Deposition Disease | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191744Phase 3 · active not recruiting Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03011814Phase 1/Phase 2 · recruiting Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Mycosis Fungoides,Sezary Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05669989Phase 2 · enrolling by invitation International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740486Phase 3 · not yet recruiting A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735637Phase 3 · not yet recruiting A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00644228Phase 3 · active not recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04140162Phase 2 · active not recruiting Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02523040Phase 2 · active not recruiting Lenalidomide for Adult Histiocyte Disorders · 863 trials list this drug (249 active) | — | — | Erdheim-Chester Disease,Histiocytic Sarcoma,Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404283Phase 3 · active not recruiting Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07719855Phase 3 · not yet recruiting A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06892522Phase 1/Phase 2 · recruiting A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717177Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma,Gray-Zone Lymphoma,Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05690984Phase 2 · active not recruiting Elimination of Minimal Residual Disease After Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07709884Phase 4 · not yet recruiting A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05469893Phase 2 · recruiting Immuno-PRISM (PRecision Intervention Smoldering Myeloma) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343042Phase 1/Phase 2 · recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649525Phase 3 · recruiting Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05351593Phase 1/Phase 2 · recruiting Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma · 863 trials list this drug (249 active) | — | — | Central Nervous System Lymphoma,Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04712097Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015880Phase 1 · recruiting Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05137054Phase 1 · recruiting A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05409066Phase 3 · active not recruiting Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06723457Phase 2 · recruiting Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma · 863 trials list this drug (249 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05283720Phase 2 · active not recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00403169Phase 2 · completed Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer · 863 trials list this drug (249 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04775550Phase 2 · active not recruiting DARA RVD For High Risk SMM · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05660967Phase 2 · terminated Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05683171Phase 1/Phase 2 · active not recruiting A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671287Phase 3 · not yet recruiting GMMG-HD11/DSMM XXI/64007957MMY3010 · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01562405Phase 1 · active not recruiting Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01829568Phase 1 · active not recruiting Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05558319Phase 3 · recruiting NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068597Phase 1/Phase 2 · recruiting Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Non-Hodgkin Lymphoma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01446133Phase 2 · active not recruiting Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) · 863 trials list this drug (249 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03901963Phase 3 · completed A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07247097Phase 2 · not yet recruiting ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07663253recruiting Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03651128Phase 3 · completed Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07428369Phase 2/Phase 3 · withdrawn A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03556332Phase 2 · active not recruiting A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01644799Phase 1 · completed Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01838434Phase 1 · completed Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150091Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06006117Phase 3 · recruiting Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma · 863 trials list this drug (249 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02232516Phase 2 · completed Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Anaplastic Large Cell Lymphoma,Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Hepatosplenic T-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04113226Phase 2 · completed Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05561387Phase 3 · recruiting Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06348147Phase 2 · withdrawn Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05776979Phase 2 · recruiting Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07018050Phase 2 · recruiting Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01702831Phase 2 · completed Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974216Phase 2 · active not recruiting Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05243797Phase 3 · recruiting Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06974786Phase 2 · recruiting Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01415752Phase 2 · active not recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04430894Phase 2 · active not recruiting KRDI in Transplant-Eligible MM · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03652064Phase 3 · completed A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05145400Phase 2 · recruiting Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Malignant Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739813Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma · 863 trials list this drug (249 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03290950Phase 2 · active not recruiting A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03106324completed A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01351896Phase 2 · active not recruiting Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 863 trials list this drug (249 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01421927Phase 1 · terminated Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06911502Phase 3 · recruiting A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05032820Phase 2 · completed Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594899Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661007Phase 1/Phase 2 · active not recruiting To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) · 863 trials list this drug (249 active) | — | — | Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02334865Phase 1 · active not recruiting SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy · 863 trials list this drug (249 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03104842Phase 2 · active not recruiting Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01556035Phase 2 · completed Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07585747Phase 2 · not yet recruiting A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01955499Phase 1 · active not recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma,Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05497804Phase 2 · active not recruiting Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504199Phase 2 · active not recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07261163Phase 2 · recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05849610Phase 2 · active not recruiting Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04126200Phase 1/Phase 2 · active not recruiting Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03477539Phase 2 · completed Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04978584Phase 2 · active not recruiting Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429268Phase 3 · active not recruiting Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05848765Phase 2 · recruiting Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy · 863 trials list this drug (249 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03173092Phase 4 · terminated A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03319667Phase 3 · active not recruiting A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05182957Phase 2 · recruiting Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07560449Phase 2 · not yet recruiting QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04653246Phase 2 · active not recruiting Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01668719Phase 1/Phase 2 · completed S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03863184Phase 2 · active not recruiting Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL · 863 trials list this drug (249 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03523975Phase 1/Phase 2 · recruiting Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06679101Phase 3 · recruiting A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01816971Phase 2 · completed Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05317416Phase 3 · active not recruiting Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02420860Phase 2 · active not recruiting Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02719613Phase 2 · completed Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02203643Phase 2 · completed Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03500445Phase 2 · active not recruiting Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984097Phase 1 · completed A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01054196Phase 1/Phase 2 · active not recruiting Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01241734Phase 1/Phase 2 · completed Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06508658Phase 3 · active not recruiting A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030699Phase 2 · withdrawn A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma · 863 trials list this drug (249 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00430365Phase 3 · completed Maintenance Therapy Using Lenalidomide in Myeloma · 863 trials list this drug (249 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06760156Phase 2 · recruiting Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym · 863 trials list this drug (249 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04824092Phase 3 · active not recruiting Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients · 863 trials list this drug (249 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04903197Phase 1 · terminated Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma · 863 trials list this drug (249 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |